39 citations,
September 2017 in “The Open Rheumatology Journal” Low serum complement levels in SLE patients don't always match with disease flares; monitoring C3 and C4 is useful, but cell-bound complement products might better indicate disease activity.
2 citations,
January 2012 in “PubMed” The study evaluated the efficacy of mycophenolate mofetil (MMF) in treating juvenile onset severe lupus nephritis. Twelve children (mean age 12.6 years) underwent 6 months of induction therapy with MMF and prednisolone, resulting in significant improvements in urine protein, serum anti-double-stranded DNA antibody, renal function, albumin, and serum C3 and C4 levels (p < 0.05). Ten children continued with 18 months of maintenance therapy, during which no renal flares occurred, and the mean prednisolone dose was reduced to 9.2 mg/day. Among 5 patients who had a second biopsy, 4 showed significant histological improvement. Major infections were reported in 5 patients, including Herpes zoster, bacteremia, and hair loss. MMF was concluded to be an effective therapy for this condition.
3 citations,
January 2023 in “The Egyptian Rheumatologist” Macrophage activation syndrome can be a deadly first sign of systemic lupus erythematosus.
213 citations,
October 2017 in “Rheumatology” The guidelines suggest a detailed approach to diagnosing and treating lupus, with a focus on regular check-ups, personalized medicine, and a range of drug options for different cases.
5 citations,
May 2023 in “Frontiers in immunology” Environmental factors like diet and vitamin levels, especially Vitamin D, can affect autoimmune diseases differently, with lifestyle changes potentially improving outcomes.